... 86 , 89 , 90 ] however, preliminary results indicate that tyrosine kinase inhibitors can be used successfully.[ 91 , 92 ] References Brunning RD, Matutes E, Harris NL, et al.: ...

... Locus-Specific Databases HGMD ClinVar TH 11p15 ​.5 Tyrosine 3-monooxygenase TH database TH TH Data are compiled from the following standard references: gene from HGNC ; chromosome locus from OMIM ; protein ...

... HGMD ClinVar ALK 2p23 ​.2-p23.1 ALK tyrosine kinase receptor ALK database ALK ALK Data are compiled from the following standard references: gene from HGNC ; chromosome locus from OMIM ; protein ...

... Locus-Specific Databases HGMD ClinVar TAT 16q22 ​.2 Tyrosine aminotransferase TAT database TAT TAT Data are compiled from the following standard references: gene from HGNC ; chromosome locus from OMIM ; protein ...

... 2 TREM2 TREM2 TYROBP 19q13 ​.12 TYRO protein tyrosine kinase-binding protein TYROBP TYROBP Data are compiled from the following standard references: gene from HGNC ; chromosome locus from OMIM ; protein ...

... or a known activating pathogenic variant in the tyrosine kinase domain of the MET proto-oncogene.[ 2 , 3 ] No specific environmental risk factors have been reported to cause hereditary or sporadic papillary RCC. References Zbar B, Tory K, Merino M, et al.: ...

... Protein HGMD ClinVar DYRK1A 21q22 ​.13 Dual specificity tyrosine-phosphorylation-regulated kinase 1A DYRK1A DYRK1A Data are compiled from the following standard references: gene from HGNC ; chromosome locus from OMIM ; protein ...

... Locus-Specific Databases HGMD ClinVar BTK Xq22 ​.1 Tyrosine-protein kinase BTK BTK @ LOVD BTK BTK Data are compiled from the following standard references: gene from HGNC ; chromosome locus from OMIM ; protein ...

... myofibromatosis that have PDGFRB variants when treated with tyrosine kinase inhibitors like imatinib and sunitinib, which inhibit the PDGFRB gain-of-function variant in the tumor.[ 24 - 27 ] References Rodriguez-Galindo C, Ramsey K, Jenkins JJ, et ...

... retrospective analysis reported the efficacy of the multitargeted tyrosine kinase inhibitor anlotinib in patients with recurrent metastatic osteosarcoma (cited Li et al. as reference 36). The study included 15 patients who were ...